Compare PRDO & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRDO | TSHA |
|---|---|---|
| Founded | 1994 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 1997 | 2020 |
| Metric | PRDO | TSHA |
|---|---|---|
| Price | $34.00 | $6.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $42.00 | $11.63 |
| AVG Volume (30 Days) | 770.4K | ★ 2.8M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | ★ 10.50 | 5.56 |
| EPS | ★ 1.60 | N/A |
| Revenue | ★ $581,296,000.00 | $9,773,000.00 |
| Revenue This Year | $4.28 | N/A |
| Revenue Next Year | $2.89 | $1,152.42 |
| P/E Ratio | $38.18 | ★ N/A |
| Revenue Growth | N/A | ★ 17.28 |
| 52 Week Low | $26.66 | $2.69 |
| 52 Week High | $38.50 | $7.30 |
| Indicator | PRDO | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 48.66 | 57.18 |
| Support Level | $31.43 | $5.28 |
| Resistance Level | $32.79 | $6.76 |
| Average True Range (ATR) | 1.40 | 0.35 |
| MACD | 0.14 | 0.08 |
| Stochastic Oscillator | 60.07 | 83.46 |
Perdoceo Education Corp is an American for-profit education company that focuses on quality postsecondary education online to a diverse student population, along with campus-based and blended learning programs. The company's important segments include the American InterContinental University, the University of St. Augustine for Health Sciences, and Colorado Technical University. These universities provide undergraduate, graduate, and doctoral degree programs focusing on business, technology, management, and social services, with the majority of the students enrolled in programs offered fully online. The majority of the its revenue comes from the Colorado Technical University segment.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.